Anticipating that the market will continue to stage a recovery, and possibly even return to all-time highs next year, the author of today’s article notes that “investors are scanning the Street for compelling plays, hoping to snap up stocks before share prices set off on an upward trajectory. For more risk-tolerant investors, penny stocks, or names trading for less than $5 per share, are taking center stage.” As such, she proceeds to highlight two “Strong Buy” rated biotech penny stocks with “sky-scraping upside potential”. For more, CLICK HERE.
